이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck

Neoadjuvant Afatinib Based Treatment Strategies Followed by Surgery in Squamous Cell Carcinoma of the Head and Neck: an EORTC NOCI-HNCG Window Study.

The general objectives are to evaluate the pre-operative activity and the safety of afatinib in head and neck cancer and to explore the different downstream molecular pathways to identify tumor response and resistance mechanisms. The results from this study can be used to conduct a larger trial that would allow us to confirm or validate the hypotheses generated.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

This is a randomized, multicenter early phase II trial exploring the pre-operative activity of afatinib vs. nontreatment. The study includes an early monitoring of the surgical co-morbidities for patients treated with afatinib and accrual may be stopped prematurely according to a pre-defined safety stopping rule.

Patients will be randomized with a 5:1 ratio, between the two arms: afatinib and 'no treatment'. It is intended to include a total of 30 eligible patients out of which 25 patients will be randomized into the afatinib arm.

Patients allocated to the 'no treatment' arm will mainly serve as a reference to interpret the results of the translational research part of the study although no formal comparison between the afatinib arm and the 'no treatment' arm is intended.

Patients will be first registered into the EORTC system after signing the informed consent form. The site will have to complete all the study related procedures within 4 weeks prior randomization and all eligibility criteria should be met before the patient can be randomized into the study.

The registration of patients will proceed with slots for patients which will be opened or closed based on the randomization of patients into the afatinib arm. Starting with 3 free slots, an additional slot will become available for each patient randomized to the 'no treatment' arm.

Registration will be paused after three completes the 4 week observation period after surgery. Similar action will be done after the next 3 patients have been entered into the afatinib arm.

Once the first 6 patients in the afatinib arm have been observed for surgical toxicities of grade ≥ 3 for 4 weeks following surgery, the slot system will cease to operate.

연구 유형

중재적

등록 (실제)

30

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Brussels, 벨기에, 1000
        • Institut Jules Bordet
      • Brussels, 벨기에, 1200
        • Cliniques Universitaires St. Luc
      • Leuven, 벨기에, 3000
        • U.Z. Leuven - Campus Gasthuisberg
      • Milano, 이탈리아, 20133
        • Istituto Nazionale per lo Studio e la Cura dei Tumori

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Newly diagnosed histologically proven squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx.
  • Patients selected for a primary surgical treatment
  • Age ≥18 years
  • Performance status ECOG 0-1
  • Within 2 weeks prior randomization:

    • Adequate bone marrow function as demonstrated by neutrophils count ≥ 1,500/mm3, platelet count ≥ 75,000/mm3, WBC ≥ 3.0/109 L
    • Adequate hepatic function as demonstrated by bilirubin < 2 times upper limit of normal (ULN), ALAT or ASAT < 3 times ULN
    • Adequate renal function as demonstrated by serum creatinine <or= 1.5 mg/dL (< 133 µmol/L) or calculated creatinine clearance ≥50 mL/min
    • Controlled blood pressure (<140/90 mm Hg) with or without antihypertensive treatment
    • Prothrombin time (PT) with an international normalized ratio (INR) <or=1.2
    • Partial thromboplastin time (PTT) <or= 1.2 times ULN
    • Adequate cardiac function assessed by 12-lead ECG and if clinically indicated echocardiography to document LVEF
    • FDG-PET/CT performed
    • DCE MRI and DWI MRI performed
  • Primary tumor ≥2 cm in their largest diameter measured bidimensionally by imaging done within 2 weeks prior to randomization
  • Availability of tumor and normal mucosa biopsies during staging endoscopy (please refer to surgical guidelines for further information).
  • Availability of blood samples for translational research
  • Absence of any serious underlying medical conditions which could impair the ability of the patient to participate in the study
  • Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and 6 months beyond stop of treatment in such a manner that the risk of pregnancy is minimized. In general, the decision for appropriate methods to prevent pregnancy should be determined by discussions between the investigator and the study subject. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal. Females should not be breast feeding.

    • Post menopause is defined as: amenorrhea ≥ 12 consecutive months without another cause or for women with irregular menstrual periods and on hormone replacement therapy (HRT), a documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL
    • Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicide) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (e.g., vasectomy) should be considered to be of childbearing potential.
    • Women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of investigational product.
    • Female patients within one year of entering the menopause must agree to use an effective non-hormonal method of contraception during the treatment period and for at least 6 months after the last study treatment.
  • Males must agree to use an effective method of contraception during the treatment period and for at least 6 months after the last study treatment.
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
  • Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations

Exclusion Criteria:

  • Patients with nasopharynx, nasal cavity and paranasal sinuses carcinomas, or recurrent/metastatic SCCHN are not eligible for this study
  • T3 -T4 hypopharyngeal SCCHN are excluded.
  • Distant metastases
  • Active second malignancy during the last five years except non melanomatous skin cancer or carcinoma in situ of the cervix
  • Prior chemotherapy, radiotherapy or targeted therapy including HER inhibitors (monoclonal antibodies or tyrosine kinase inhibitors) for SCCHN
  • Concomitant use of potent P-gp inhibitors, potent P-gp inducers or Erythropoietin (EPO)
  • Evidence of diabetes
  • Evidence of interstitial lung disease
  • Weight loss of more than 10% in the previous 6 months
  • Participation in another interventional clinical trial in the preceding 30 days prior to randomization

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Afatinib
Afatinib given orally for 2 weeks after randomization till day -1 prior to surgery (day 0) at a dose of 40 mg/day
Afatinib for 2 weeks at a dose of 40 mg/day
다른: Observation
No treatment only observation
관찰

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Reduction of tumor Standardised Uptake Volume as assessed by FDGPET
기간: Baseline and after two weeks of treatment
Afatinib will be given orally for 2 weeks from the day of randomization until day -1 prior to surgery at a dose of 40 mg/day.Pre-treatment biopsies and blood samples will be harvested during the regular diagnosis staging procedure and at surgery.FDG-PET/CT-scan and MRIs will be performed before treatment (before day -15) and the day before surgery.The primary outcome measure is the reduction in the tumor standardised uptake volume as assessed by FDGPET
Baseline and after two weeks of treatment

2차 결과 측정

결과 측정
측정값 설명
기간
Evaluation of tumour response to treatment by different imaging modalities like DWIMRI and DCEMRI
기간: Baseline and after two weeks of treatment

Response after 2 weeks of treatment, prior to surgery, evaluated by:

  • RECIST v1.1 using conventional imaging
  • Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI)
  • Diffusion Weighted Imaging Magnetic Resonance Imaging (DWI MRI)
Baseline and after two weeks of treatment

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 연구 의자: Jean-Pascal Machiels, MD, European Organisation for Research and Treatment of Cancer - EORTC
  • 수석 연구원: Lisa Licitra, MD, European Organisation for Research and Treatment of Cancer - EORTC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2012년 7월 1일

기본 완료 (실제)

2015년 8월 1일

연구 완료 (실제)

2015년 8월 1일

연구 등록 날짜

최초 제출

2012년 2월 20일

QC 기준을 충족하는 최초 제출

2012년 2월 23일

처음 게시됨 (추정)

2012년 2월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2018년 7월 9일

QC 기준을 충족하는 마지막 업데이트 제출

2018년 7월 6일

마지막으로 확인됨

2018년 7월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • EORTC-90111-24111
  • 2011-005820-17 (EudraCT 번호)

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .